Top Markets
Coin of the day
Cypherpunk Technologies Inc. Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc.

CYPH
Rang in aandelen #19166
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the... Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
Aandeelprijs
$1.62
Laatst gesynchroniseerd: 2026-08-25
Marktkapitalisatie
$172.47M
Verandering (1 dag)
-3.57%
Verandering (1 jaar)
446.74%
Land
US
Handel Cypherpunk Technologies Inc. (CYPH)

Categorie

P/B-ratio voor Cypherpunk Technologies Inc. (CYPH)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Cypherpunk Technologies Inc. is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor Cypherpunk Technologies Inc. van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH